SBIR/STTR Research Award

Centralized assay datasets for modelling support of small drug discovery organizations

Award identifier 77473f32481b21e359dbb6bb571212c79b07d99343b76f9325d62d5b39a76ae1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,575,776

Program and phase

SBIR · Phase II

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
COLLABORATIONS PHARMACEUTICALS INC
Proposal award date
2018-08-01
Contract end date
2020-07-31
UEI
EFJCLL37KKH3
Solicitation number
PA18-591
Topic code
NIGMS

Research abstract

Project Summary We have recently used computational models to identify the protease inhibitor indinavirused as an antiviral for HIVas a positive allosteric modulator at thenicotinic acetylcholine receptorWe now propose to build on this discovery as well as other publications describing compounds that are positive allosteric modulators of thenicotinic acetylcholine receptorWe propose identifying further compounds that possess activity against this or one ofother targets implicated in Alzheimer s disease using a combination of Bayesian machine learning and in vitro assaysGenerating such data will enable us to potentially provide more specific compounds as well as building datasets that can be used to build predictive models to identify additional compounds with activity at these Alzheimer s targetsThese combined efforts should in the first instance provide commercially viable treatments which will be used to experimentally validate our computational models that can be shared with the Alzheimer s disease scientific communityWe are proposing to build and validate models based on public databasesselect compounds for testing and use the data generated as a starting point for further optimization Project Narrative Alzheimer s diseaseADis one of the most common neurodegenerative disorders that causes dementia and it is characterized by amyloid deposition of aAA peptideAprocessed from the amyloid precursor proteinAPPand neurofibrillary tanglesNFTMany palliative drugs are available for the disease but there is still an urgent need for curative drugs with greater efficacyWe need to understand the key factors involved in disease progression and their suitability as drug targets for discovering new drugs against Alzheimerandapos s diseaseWe hence propose to study several of these targets for Alzheimer s disease involving all the key steps in the pathwayincluding several old and new targetsWe will use ourAssay Centralsoftware to compile structure activity data for building computational modelsthat can be used to selected compounds to test activity in vitro as a starting point for further optimization

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

18 SBIR/STTR records share this UEI (2016–2025). Reported award amounts total $20,250,279. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.